Related Experiment Video
Updated: May 12, 2026
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
Optimal time interval between neoadjuvant chemoradiotherapy and surgery for rectal cancer
D A M Sloothaak1, D E Geijsen, N J van Leersum
1Department of Surgery, Academic Medical Centre, Amsterdam, The Netherlands.
The British Journal of Surgery
|March 29, 2013
Summary
For rectal cancer patients receiving neoadjuvant chemoradiotherapy (CRT), delaying surgery to 15-16 weeks after CRT initiation significantly increases the chance of pathological complete response (pCR). This optimal timing maximizes treatment effectiveness for better outcomes.
Area of Science:
- Oncology
- Surgical Oncology
- Radiotherapy
Background:
- Neoadjuvant chemoradiotherapy (CRT) improves local control in rectal cancer.
- Optimal timing for surgery post-CRT remains unclear.
- Population-level analysis is needed to understand timing's impact on pathological response.
Purpose of the Study:
- To analyze the influence of surgical timing variations after neoadjuvant CRT on pathological response in rectal cancer.
- To determine the optimal interval between CRT and surgery for maximizing treatment efficacy.
Main Methods:
- Retrospective analysis of 1593 rectal cancer patients from the Dutch Surgical Colorectal Audit (2009-2011).
- Patients categorized by interval between start of CRT and surgery: <13, 13-14, 15-16, and >16 weeks.
- Primary endpoint: pathological complete response (pCR; ypT0N0).
Main Results:
- The 15-16 week interval group showed the highest pCR rate (18.0%, P=0.013).
- This interval was independently associated with higher pCR (HR 1.63).
- Significant differences observed in clinical tumor (cT4) and metastasis (cM1) categories across intervals.
Conclusions:
- Delaying rectal cancer surgery to 15-16 weeks post-CRT initiation appears to maximize the likelihood of achieving a pathological complete response.
- This interval also showed favorable trends for tumor and nodal downstaging.
